摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3,5-diamino-6-chloro-N-[N'-[(3S)-1-[[6-(trifluoromethyl)pyridin-3-yl]methyl]-1-azoniabicyclo[2.2.2]octan-3-yl]carbamimidoyl]pyrazine-2-carboxamide

中文名称
——
中文别名
——
英文名称
3,5-diamino-6-chloro-N-[N'-[(3S)-1-[[6-(trifluoromethyl)pyridin-3-yl]methyl]-1-azoniabicyclo[2.2.2]octan-3-yl]carbamimidoyl]pyrazine-2-carboxamide
英文别名
——
3,5-diamino-6-chloro-N-[N'-[(3S)-1-[[6-(trifluoromethyl)pyridin-3-yl]methyl]-1-azoniabicyclo[2.2.2]octan-3-yl]carbamimidoyl]pyrazine-2-carboxamide化学式
CAS
——
化学式
C20H24ClF3N9O+
mdl
——
分子量
498.9
InChiKey
JBOGOYJHBXIIQZ-VGKUZZGFSA-O
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2
  • 重原子数:
    34
  • 可旋转键数:
    5
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.45
  • 拓扑面积:
    158
  • 氢给体数:
    4
  • 氢受体数:
    10

文献信息

  • HETEROCYCLIC COMPOUNDS, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF AND PROCESSES FOR THE PREPARATION THEREOF
    申请人:Boehringer Ingelheim International GmbH
    公开号:EP2897940B1
    公开(公告)日:2019-05-01
  • ORGANIC ELECTROLUMINESCENCE DEVICE
    申请人:TAKADA Saki
    公开号:US20110073848A1
    公开(公告)日:2011-03-31
    A material for a light emitting device containing a compound represented by the following formula (1): wherein each A independently represents a nitrogen atom or a carbon atom, which may have a substituent, and each of the rings consisting of A and nitrogen atoms independently represents an aromatic ring or an aromatic heterocyclic ring; and L represents a divalent linking group.
  • US8841309B2
    申请人:——
    公开号:US8841309B2
    公开(公告)日:2014-09-23
  • [EN] HETEROCYCLIC COMPOUNDS, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF AND PROCESSES FOR THE PREPARATION THEREOF<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES, MÉDICAMENTS CONTENANT CES COMPOSÉS, LEUR UTILISATION ET PROCÉDÉS DE LEUR PRÉPARATION
    申请人:BOEHRINGER INGELHEIM INT
    公开号:WO2014044849A1
    公开(公告)日:2014-03-27
    The present invention relates to compounds of general formula (I), and the tautomers and the salts thereof, particularly the pharmaceutically acceptable salts thereof, which have valuable pharmacological properties, particularly an inhibitory effect on epithelial sodium channels, the use thereof for the treatment of diseases, particularly diseases of the lungs and airways.
查看更多